Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2008

Presentation of Phase IIa Efficacy Results

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy results of a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent in-vitro and in-vivo anti-hepatitis C (HCV) effect. Data indicates that Debio 025 shows an important additive anti-HCV effect when co-administered with pegylated Interferon (Peg-IFN) alpha-2a to treatment- naive HCV patients. Debiopharm presented these findings at the 43rd Annual Meeting of the European Association for the Study of the Liver, in Milan, Italy.

The double-blind, placebo-controlled study investigated different dose regimens of Debio 025 in combination with alpha-2a Peg-IFN 180 Mug/week in treatment naive chronic HCV mono-infected patients. Ninety patients were randomised to receive either of the following treatment regimens during 29 days: Peg-IFN with placebo; Peg-IFN with Debio 025 200 mg/day; Peg-IFN with Debio 025 600 mg/day; Peg-IFN with Debio 025 1000 mg/day; and Debio 025 1000 mg/day.

In patients with genotypes 1 and 4, at day 29, the HCV-RNA reduction was -4.6 log10 IU/mL in the Peg-IFN with Debio 025 600 mg/day arm, and -4.8 log10 IU/mL in the Debio 025 1000 mg/day arm. This was significantly different (p< 0.05) from the Peg-IFN with placebo, as well as the Debio 025 1000 mg/day monotherapy arms, in which the reduction in viral load was respectively -2.49 and -2.20. In these two arms, at day 29, the proportion of subjects with undetectable viral load was 25%. This number increased to 66% in the Peg-IFN with Debio 025 1000 mg/day group.

"To obtain these exciting results after an administration period of only one month is promising and demonstrates that Debio 025 will be a breakthrough in the treatment of HCV infections," said Kame
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
9. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... - CytRx Corporation,(NASDAQ:CYTR) today announced positive results ... lead drug candidate,arimoclomol significantly accelerated the recovery ... rat model of stroke, even when,treatment was ... stroke was,induced. These data confirm and expand ...
... PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: ... the independent Data Monitoring Committee,("DMC") of the Company's ... of sickle cell disease in adults, the,DMC recommended ... low,probability of achieving a reduction in crisis rate, ...
Cached Medicine Technology:CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... October 20, 2014 JZ Fitness, an ... coaching, corporate wellness programming, authorship, international lecturing and community ... to announce the release of the JZ Fitness nutrition ... years of coaching thousands of individuals on nutrition, Jenn ... that does not require calorie counting or cumbersome food ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... guideline on colorectal cancer screening released today by ... health care organizations, including the American College of ... (ASGE) and the American Cancer Society (ACS), offers ... and states a strong preference for screening tests ...
... National Naval Medical Center in Bethesda, Maryland Coincides, With Sleep ... ... Awareness Week, DALLAS, March 6 /PRNewswire/ - The ... importance for Dr. Keith Thornton,third-generation Dallas dentist and recognized expert on the ...
... Centers, Inc.,("GNC" or the "Company"), the largest global ... results for the,quarter and year ended Dec. 31, ... indirect wholly-owned subsidiary,of GNC Parent LLC, which was ... Management LLC and Ontario Teachers, Pension Plan Board. ...
... CARLSBAD, Calif., March 6 Genoptix, Inc.,(Nasdaq: GXDX ... participation in the Cowen and Company 28th Annual Health,Care ... Boston, Mass.,March 17 - 20, 2008., Dr. Tina ... COO, will present at the conference on Monday, March ...
... Quarterly Revenue and Returns to Profitability ... First Half 2008 Financial Guidance ... Time, NASHUA, N.H., March 6 iCAD, Inc. (Nasdaq:,ICAD), ... detection of cancer, today announced financial,results for the fourth quarter ...
... Adjusted EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ ... of products and services to the global life,sciences markets, ... MDS reported net revenues of $296 million, net income ... of $0.14.,Adjusted EBITDA rose to $40 million, up from ...
Cached Medicine News:Health News:New guidelines update recommendations on colorectal cancer screening 2Health News:New guidelines update recommendations on colorectal cancer screening 3Health News:New guidelines update recommendations on colorectal cancer screening 4Health News:Dallas Dentist Trains Navy Dentists on New Therapy to Treat Snoring and Obstructive Sleep Apnea 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 3Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 4Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 5Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 6Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 7Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 8Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 9Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 10Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 11Health News:Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13
... Vitatron T-series is a new top-line range ... bradycardia and Atrial Fibrillation (AF). Because the ... for AF, the treatment of AF is ... digital technology the heart rhythm is monitored ...
... Xper is the perfect partner for growing ... systems are scalable to meet your needs ... means that your Allura Xper FD20 system ... use. Openness to new technologies allows you ...
... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...
... Volume coverage, not slices, changes the ... are performed. The LightSpeed VCT Series of ... making the imaging of difficult patients or ... groundbreaking technology opens the door to new ...
Medicine Products: